



OPEN ACCESS

ORIGINAL ARTICLE

Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database

Pål Møller,¹ Toni Seppälä,² Inge Bernstein,^{3,4} Elke Holinski-Feder,^{5,6} Paola Sala,⁷ D Gareth Evans,^{8,9} Annika Lindblom,¹⁰ Finlay Macrae,^{11,12} Ignacio Blanco,¹³ Rolf Sijmons,¹⁴ Jacqueline Jeffries,¹⁵ Hans Vasen,¹⁶ John Burn,¹⁷ Sigve Nakken,^{18,19} Eivind Hovig,^{18,19,20} Einar Andreas Rødland,¹⁸ Kukatharmini Tharmaratnam,²¹ Wouter H de Vos tot Nederveen Cappel,²² James Hill,²³ Juul Wijnen,²⁴ Kate Green,⁸ Fiona Laloo,⁸ Lone Sunde,^{3,25,26} Miriam Mints,²⁷ Lucio Bertario,⁷ Marta Pineda,¹³ Matilde Navarro,¹³ Monika Morak,^{5,6} Laura Renkonen-Sinisalo,^{28,29} Ian M Frayling,¹⁵ John-Paul Plazzer,¹¹ Kirsi Pylvanainen,³⁰ Julian R Sampson,¹⁵ Gabriel Capella,¹³ Jukka-Pekka Mecklin,^{30,31} Gabriela Möslin,³² in collaboration with The Mallorca Group (<http://mallorca-group.eu>)

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/gutjnl-2015-309675>)

For numbered affiliations see end of article.

Correspondence to

Dr Pål Møller, Research Group Inherited Cancer, The Norwegian Radium Hospital, Oslo 0310, Norway; moller.pal@gmail.com

Received 27 March 2015

Revised 6 November 2015

Accepted 17 November 2015

Published Online First

9 December 2015

ABSTRACT

Objective Estimates of cancer risk and the effects of surveillance in Lynch syndrome have been subject to bias, partly through reliance on retrospective studies.

We sought to establish more robust estimates in patients undergoing prospective cancer surveillance.

Design We undertook a multicentre study of patients carrying Lynch syndrome-associated mutations affecting *MLH1*, *MSH2*, *MSH6* or *PMS2*. Standardised information on surveillance, cancers and outcomes were collated in an Oracle relational database and analysed by age, sex and mutated gene.

Results 1942 mutation carriers without previous cancer had follow-up including colonoscopic surveillance for 13 782 observation years. 314 patients developed cancer, mostly colorectal (n=151), endometrial (n=72) and ovarian (n=19). Cancers were detected from 25 years onwards in *MLH1* and *MSH2* mutation carriers, and from about 40 years in *MSH6* and *PMS2* carriers. Among first cancer detected in each patient the colorectal cancer cumulative incidences at 70 years by gene were 46%, 35%, 20% and 10% for *MLH1*, *MSH2*, *MSH6* and *PMS2* mutation carriers, respectively. The equivalent cumulative incidences for endometrial cancer were 34%, 51%, 49% and 24%; and for ovarian cancer 11%, 15%, 0% and 0%. Ten-year crude survival was 87% after any cancer, 91% if the first cancer was colorectal, 98% if endometrial and 89% if ovarian.

Conclusions The four Lynch syndrome-associated genes had different penetrance and expression. Colorectal cancer occurred frequently despite colonoscopic surveillance but resulted in few deaths. Using our data, a website has been established at <http://LScarisk.org> enabling calculation of cumulative cancer risks as an aid to genetic counselling in Lynch syndrome.

Significance of this study

What is already known on this subject?

- Inherited colorectal cancer may be caused by mismatch repair gene mutations and is then commonly referred to as Lynch syndrome.
- Lynch syndrome is under-recognised and results in about 0.1% of the population having a significantly increased risk of early onset colorectal, endometrial and ovarian cancer.
- Endoscopic surveillance with removal of precursor adenomas is recommended to prevent colorectal cancer.

What are the new findings?

- This is the first comprehensive prospective study to provide empirically observed data on colorectal cancer incidence and survival in Lynch syndrome.
- Colorectal cancer occurred despite colonoscopic surveillance with removal of adenomas.
- Colonoscopic surveillance with early detection and treatment of invasive colorectal cancer was associated with excellent survival. Survival after first endometrial or ovarian cancer was also excellent.
- Revised estimates of the different penetrance and expression patterns in carriers of *MLH1*, *MSH2*, *MSH6* and *PMS2* mutations.



CrossMark

To cite: Møller P, Seppälä T, Bernstein I, et al. *Gut* 2017; **66**:464–472

Significance of this study

How might it impact on clinical practice in the foreseeable future?

- ▶ The results validate the continued use of colonoscopy to prevent colorectal cancer death.
- ▶ Very high cure rate after endometrial and ovarian cancer may call into question the place of risk reducing oophorectomy and/or hysterectomy.
- ▶ *MSH6* and possibly *PMS2* mutation carriers have low cancer risk before 40 years of age.
- ▶ Individual risk estimation should be based on mutated gene, gender and age.

INTRODUCTION

Lynch syndrome (LS) is associated with a high probability of GI, gynaecological and other cancers. It is caused by inherited mutations affecting any of four DNA mismatch repair (MMR) genes, *MSH2*, *MLH1*, *PMS2* or *MSH6*, or by a deletion in the *EPCAM* gene, which leads to methylation of the adjacent *MSH2* promoter. It is an under-recognised condition accounting for about 1–3% of colorectal cancers (CRCs) in the population.¹ To date, most LS patients have been identified following investigation because of their family or personal histories of multiple and/or early-onset cancers.

Carriers of pathogenic *MLH1*, *MSH2*, *MSH6* or *PMS2* mutations require reliable information about their future cancer risk so that they can be offered appropriately targeted surveillance, but published risk estimates are extremely variable. One obvious factor is reliance on retrospective data. Another is the impact of initial selection criteria for molecular testing. In clinical practice, these have included the Amsterdam I or Amsterdam II criteria, the Bethesda guidelines or simply age at cancer diagnosis. Previous estimates of the cumulative risk at 70 years for CRC in *MLH1* or *MSH2* mutation carriers range from 22% to 74%. Mutations in *MSH6* and *PMS2* genes have lower penetrance and different patterns of expression: *MSH6* mutation carriers are thought to have a high risk of endometrial cancer, similar to that in *MSH2* mutation carriers, but lower risks of CRC. For a comprehensive and updated overview of literature, see two recently published reviews by us and others.^{1 2}

Colonoscopy enables the identification and removal of preinvasive neoplasia or early cancers in the absence of symptoms, and is the mainstay of secondary prevention in LS patients. Although adenoma removal is considered to represent a surrogate for the prevention of CRC and death, the evidence supporting this assumption in LS is controversial.^{1–11}

The European 'Majorca group' (<http://mallorca-group.eu>) and colleagues in the International Society for Gastrointestinal Hereditary Tumours (<http://insight-group.org>) have developed a pooled prospective database of LS mutation carriers to better characterise their cancer risks and the effects of interventions. This first report focuses on the cumulative incidence of first cancers and associated survival.

PATIENTS AND METHODS**The LS prospective database**

Data were stored and organised as an Oracle relational database adapting the core structure of CGEN.¹² This structure has the capability for later addition of other information and classes of

information to the patients already filed and for inclusion of new patients. Data were manipulated by TOAD inside Oracle and exported by TOAD to SYSTAT13 and Excel for further manipulations and statistical calculations.

The variables used for this first report were age at inclusion for follow-up, gender, age at most recent observation, age at death, mutated gene, age at diagnosis of any cancer, age at complete surgical removal of organs and which preventive modalities had been applied. Cancer diagnoses were scored by using the first three positions in the International Classification of Disease, ninth revision system. Ages were scored as integers.

Patients and interventions

Each centre had identified each patient to be at increased risk of CRC according to internationally recognised guidelines^{1 2} or local adaptations of these. Patients had then been subject to follow-up by colonoscopy and modalities for early detection of endometrial and ovarian cancer, and mutational analysis of the MMR genes. All patients in this study were proven or obligate carriers of pathogenic mutations as judged by the reporting centre in the *MLH1*, *MSH2*, *MSH6* or *PMS2* genes at the time of reporting. *EPCAM* mutations that lead to methylation of the adjacent *MSH2* promoter were included and scored as *MSH2* mutations. The mutations were assumed to be germline, regardless of when they were identified. All mutations reported in the 1942 patients were searched for in the Leiden open variant database (LOVD) database (http://chromium.lovd.nl/LOVD2/colon_cancer/) during October 2015: 1310 patients (67%) had pathogenic (class 5) mutations, 28 patients (1%) had probably pathogenic (class 4) mutations and the remaining 604 were not reported in LOVD.

All analysed observations were prospective, commencing when the patients were subjected to their first prospectively planned colonoscopy after being identified as at risk for colon cancer. For the purpose of this report, cases with any cancer prior to or at the same age as first colonoscopy (prevalent cancers) were excluded, as were all cases with <1 year of prospective observation time. This was done to avoid selection bias based on ascertainment and to ensure that no patient had any sign or symptom of cancer at inclusion.

The surveillance guidelines included follow-up aimed at diagnosis of colorectal adenomas or early CRC and in many centres endometrial cancer and ovarian cancer, as well as cancer awareness for all cancers known to be associated with LS. Surveillance and management guidelines have changed over time, and collaborating centres were subject to local/national decisions on how to practise at different times. None of these variations were used as variables in the present study. A detailed, referenced description of follow-up and compliance is provided in online supplementary table S2. The table and the references included there show that from the outset the reporting centres used different intervals between colonoscopies, but that from around 1996 onwards all except for the Finnish centre followed the emerging international guidelines advocating a 2-year interval or less. Intervals between gynaecological examinations were in general shorter. As previously published in the references given in the table, all visible adenomas at colonoscopies were removed. The references also show that precursor lesions were less frequently found in the endometrium or ovaries. In short, secondary prevention of colon cancer by identifying and removing precursor/early lesions was found to be promising, while this was not the case for endometrial and ovarian cancer. In consequence, all centres continued the colonoscopic surveillance, while some advised prophylactic hysterectomy and

oophorectomy to prevent gynaecological cancers. All patients reported to the database had complete data sets, and there were no missing values.

Some centres had previously reported the observed incidence of cancer in their series but with different methods to those used in this report.^{3–11} One group had reported previously on survival.⁴ The intention of this report was to compile all information available on prospectively observed outcomes in LS patients without previous cancer and patients who were previously reported are included in the current report.

Annual and cumulative incidence rates

Each patient was observed from age at inclusion to age at last observation or age at first cancer, whichever came first. Each patient was counted only once, irrespective of how many synchronous cancers the patient might have had as first cancers. Cancers that occurred after the first cancer were not considered in this study. Since surveillance before 25 years and after 70 years of age is not specified in current management guidelines and is inconsistent in practice, annual incidence rates (AIRs) outside 25–70 years were not calculated. For each patient, the numbers of years observed in each 5-year interval from 25 to 70 years of age were counted. All first cancers were scored according to age at diagnosis. The AIR for a given age group was derived by dividing the number of cancers observed by the sum of observation years in that age group.

Cumulative incidences for gynaecological cancers and prostate cancers were considered for appropriate genders separately, and observation time was censored at hysterectomy and oophorectomy when considering incidences for such cancers separately.

Cumulative incidence, denoted by Q , was computed starting at age 25, assuming zero incidence before age 25, using the formula $Q(\text{age}) = Q(\text{age}-1) + [1 - Q(\text{age}-1)] \cdot \text{AIR}(\text{age})$, where $\text{AIR}(\text{age})$ is the AIR as estimated from the corresponding 5-year interval.

SE for AIR was estimated as $\text{SEAIR} = \sqrt{\text{AIR} \cdot (1 - \text{AIR}) / \text{Yrs}}$, where Yrs denotes the number of observation years in the 5-year age group for which AIR is estimated. For cumulative incidence, the hazard rate $H = -\ln[1 - \text{AIR}]$ was used with SE estimated $\text{SEH} = \text{SEAIR} / (1 - \text{AIR})$. The SE, denoted by SEQ , of the cumulative incidence $Q(\text{age})$ up to the given age is computed in two steps. First, for each 5-year age interval, having hazard rate H with SE SEH , the contribution to the cumulative hazard from that interval is $N \cdot H$ with SE $N \cdot \text{SEH}$, where N is the number of years from that 5-year interval: for example, the cumulative incidence up to age 32 contains all 5 years from the 25–29 age interval, but only 3 years from the 30–34 age interval. The accumulated hazard CH is computed by adding the $N \cdot H$ values across age intervals, while the corresponding SE, SECH , is found by setting SECH^2 equal to the sum of $(N \cdot \text{SEH})^2$ across age intervals. The accumulated hazard rate CH should now equal $-\ln[1 - Q]$ with Q as computed above, while the SE of the cumulative incidence is computed as $\text{SEQ} = \text{SECH} / (1 - Q)$. We estimated 95% CIs as $\text{AIR} \pm 1.96 \text{SEAIR}$ and $Q \pm 1.96 \text{SEQ}$.

Survival

Follow-up continued after the occurrence of first cancers, and all patients were either reported to be alive or validated to be alive in population register on the day each patient was censored. Crude survival was calculated by the Kaplan–Meier algorithm as time from first cancer to last observation/death. Cancer stages at diagnosis and causes of death were not considered in this report.

RESULTS

Patients included and cancers diagnosed

In total, 1942 MMR mutation carriers were included: 944 *MLH1*, 616 *MSH2*, 305 *MSH6* and 77 *PMS2*. Of these, 1057 were females and 885 were males. They were observed for a total of 13 782 years (mean observation time 7.1 years), including 6518 male and 7264 female observation years. Countries of origin are detailed in table 1.

Mean ages at inclusion were 35.6 years for *MLH1* mutation carriers, 37.7 years for *MSH2* mutation carriers, 43.0 years for *MSH6* mutation carriers and 47.1 years for *PMS2* carriers. Observation years were 7954 for *MLH1* mutation carriers, 4021 *MSH2*, 1555 *MSH6* and 313 for *PMS2*. Details when stratifying on both gene and gender are given in table 1. The numbers were considered sufficient to stratify the findings on gender, mutated gene, 5-year age cohorts and cancers in specific organs. Although the numbers of *PMS2* mutation carriers were limited, they are included in all results presented.

Cancers diagnosed

Among the 1942 patients, 314 had prospectively identified first cancers (table 2), of which 151 were colorectal, 72 endometrial and 19 ovarian. Of note, 21 patients had two synchronous first cancers.

In total, 186 females had had their uterus removed and 153 had had removal of the ovaries prior to any cancer diagnosis, reducing observations years when calculating the AIR for endometrial and ovarian cancer (see online supplementary table S1).

Table 1 Numbers of patients included, observation years, mean observation years and mean age at inclusion for total series, by country of origin and by gene and gender

	Number	Obs_years	Mean_obs_years (range)	Mean_age_inclusion (range)
All	1942	13 782	7.1 (1–33)	37.8 (10–84)
By country of origin				
Finland	624	5399	8.6 (1–30)	36.1 (18–84)
Denmark	347	1852	5.3 (1–17)	39.6 (17–73)
Italy	167	1444	8.6 (1–33)	34.0 (10–65)
Norway	191	1309	6.9 (1–20)	38.4 (18–70)
The UK	195	990	5.1 (1–16)	40.0 (19–75)
Sweden	102	892	8.7 (1–20)	39.3 (18–81)
Australia	77	701	9.1 (1–29)	34.5 (19–56)
Holland	114	575	5.0 (1–28)	42.1 (19–78)
Germany	54	321	5.9 (1–26)	38.8 (20–72)
Spain	66	299	4.5 (1–14)	40.0 (18–75)
By gene and gender				
MLH1				
Females	514	4113	8.0 (1–33)	36.1 (18–84)
Males	430	3815	8.9 (1–30)	35.1 (10–81)
MSH2				
Females	325	2100	6.5 (1–30)	37.9 (17–73)
Males	291	1895	6.5 (1–26)	37.5 (15–70)
MSH6				
Females	170	846	5.0 (1–16)	43.1 (19–79)
Males	135	701	5.2 (1–28)	42.6 (10–72)
PMS2				
Females	48	205	4.3 (1–20)	45.9 (24–78)
Males	29	107	3.7 (1–12)	48.2 (26–75)

Table 2 First cancers prospectively diagnosed by International Classification of Disease, ninth revision (ICD-9) diagnoses, groups of diagnoses and stratified on gender in Lynch syndrome (LS) patients without prior or prevalent cancer at first colonoscopy

Group	ICD-9	Organ	Females	Males	Total
Colorectal cancers	153	Colon	59	72	131
	154	Rectum/sigmoid	10	10	20
Endometrial and ovarian cancers	182	Endometrium	72		72
	183	Ovary	19		19
Upper GI cancers	151	Stomach	3	5	8
	152	Duodenum	3	3	6
	156	Biliary duct/gall bladder	4	1	5
	157	Pancreas	3	2	5
Urinary tract cancers	188	Urinary bladder		4	4
	189	Kidney/ureter	6	7	13
Other LS or possibly LS cancers	173*	Skin*	6	6	12
	174	Breast	15		15
	191	Brain	1		1
	185	Prostate		6	6
Other cancers	150	Oesophagus		1	1
	159	Abdominal unspecified		1	1
	160	Nose	1		1
	161	Larynx	1	1	2
	162	Trachea		1	1
	170	Osteosarcoma	1	1	2
	172	Melanoma	2		2
	180	Cervix	1		1
	186	Testes		1	1
	193	Thyroid		1	1
	194	Neuroendocrine		2	2
	202	Lymphoma		1	1
	204	All/cll	1		1
	208	Leukaemia unspecified		1	1
Any cancer			208	127	335

*Includes both epithelial skin cancer that is often not reported, and sebaceous gland invasive cancer. This specific diagnosis may not have been uniformly reported from the different centres.

Cancer incidences

Calculated cumulative incidence for any cancer at age 70 years was 75% in females and 58% in males. This sex difference was evident from 50 years of age onwards. Sex-specific cumulative cancer incidence is detailed in table 3.

The calculated cumulative cancer incidence by age 70 years was high in *MLH1* and *MSH2* (72%) carriers and lower (at borderline significance) in *MSH6* (54%) and *PMS2* (18%) carriers. The calculated cumulative incidence of cancer at age 70 years

Table 3 Calculated sex-specific cumulative cancer incidences at 40, 50, 60 and 70 years for Lynch syndrome (LS) patients in the total series in LS patients without prior or prevalent cancer at first colonoscopy

Age	Cumulative incidence any cancer by age and gender (95% CI)	
	Females	Males
40	15% (10.3 to 19.9)	14% (9.2 to 18.8)
50	40% (34.4 to 46.0)	33% (27.1 to 39.4)
60	60% (54.6 to 66.2)	50% (42.7 to 56.7)
70	75% (68.7 to 81.3)	58% (49.9 to 65.7)

for LS patients from different current ages onwards and different mutated MMR genes are given in table 4.

Figure 1 shows the calculated complete distributions of time to any first cancer from 25 to 70 years of age by gene.

Table 5 shows cumulative cancer incidences from 25 years to different greater ages by mutated MMR gene, cancer type and gender. CRC cumulative incidence was high in *MLH1* (46%) and *MSH2* (35%) mutation carriers, lower in *MSH6* (20%) and lower *PMS2* (10%) mutation carriers. Endometrial cancer cumulative incidence was high for *MLH1* (34%), *MSH2* (51%) and *MSH6* (49%) mutation carriers, and this cancer was also frequent in older female *PMS2* mutation carriers (24%). Ovarian cancer was only identified in *MLH1* (11%) and *MSH2* (14%) mutation carriers and most cases were diagnosed before age 50. Upper GI and urinary tract cancers were infrequent and mostly diagnosed after age 60. In all, cancers were frequently seen in *MLH1* and *MSH2* mutation carriers from 25 years onwards but not before 40 years in *MSH6* and *PMS2* mutation carriers.

Figures 2 and 3 show the calculated complete cumulative distributions from 25 to 70 years of age for CRC and endometrial cancer, respectively, as the first cancer by gene, corresponding with the rows for CRC and endometrial cancer in table 5. To facilitate genetic counselling and clinical practice, an interactive website providing the complete distributions of all cancer groups in table 5 from any age selected by the user and counting to any greater age is available at <http://www.lscaris.org>.

Time since last colonoscopy to CRC

Table 6 demonstrates time since last colonoscopy in the 145 cases with CRC. Mean time since last colonoscopy was 31.8 months, median 27 months and range 7–123 months. Considering 2-year and 3-year interval between colonoscopies as compliant with protocol if interval <2.5 and 3.5 years, respectively, 84 cases (58%) were diagnosed within 2.5 since last colonoscopy and 115 (79%) within 3.5 years.

Survival

Overall 5-year and 10-year survival were excellent, reflecting survival for the most frequent cancers, CRC and endometrial cancer (table 7). Ovarian cancer survival also appeared to be excellent in LS patients, although the small number of cases adds uncertainty to the observation. A majority of patients also achieved 10-year survival of upper GI and urinary tract cancers, although survival rates were not as good as for the other cancers.

DISCUSSION

Our study was designed to answer three critical clinical questions in a large cohort of LS mutation carriers participating in surveillance programmes: what is the cumulative risk by age to first cancer, in which organs are first cancers most likely to occur, and what are the outcomes for these cancers? It is essential that once identified LS patients are offered reliable estimates of their future cancer risk and appropriate, individualised surveillance. This is the first study to present prospective empirical observations from multiple centres and including sufficient numbers to meet these needs. This study reports time to first cancer (penetrance of the mutated genes) and survival after first cancer diagnosed. As the database is expanded, we will later examine time to next cancer in those surviving first cancer.

We show that cumulative incidence of any cancer at age 70 years is high for all MMR gene mutation carriers, and slightly higher for females (75%) than males (58%). The cumulative incidences were 72% for *MLH1* and *MSH2* mutation

Table 4 Calculated cumulative incidences for any cancer from 25, 40, 50 and 60 years of age (current age) to 70 years of age for Lynch syndrome (LS) patients by mutated gene, in LS patients without cancer at current age in LS patients without prior or prevalent cancer at first colonoscopy

Current age	Cumulative incidence for any first cancer from current age to 70 years by mutated gene (95% CI)			
	<i>MLH1</i>	<i>MSH2</i>	<i>MSH6</i>	<i>PMS2</i>
25	72% (64.7 to 78.7)	72% (61.9 to 81.2)	54% (38.6 to 68.6)	18% (0.0 to 41.0)
40	66% (57.8 to 74.2)	67% (55.8 to 77.8)	53% (38.6 to 68.6)	18% (0.0 to 41.0)
50	53% (41.9 to 63.6)	55% (40.4 to 69.0)	43% (26.4 to 60.2)	18% (0.0 to 41.0)
60	32% (17.7 to 45.4)	33% (14.4 to 51.5)	24% (5.6 to 42.2)	0% (-)

carriers but lower in *MSH6* (52%) and *PMS2* (18%) mutation carriers. *MSH6* and *PMS2* carriers developed no cancers before 40 years of age. However, the lower number of *MSH6* and *PMS2* mutation carriers studied made the risk estimates for these genes less certain, particularly at younger ages.

Despite the screening colonoscopy carried out, CRC was the most frequent first cancer observed and had a cumulative incidence at age 70 of 46% in *MLH1* mutation carriers, and 35% in *MSH2* mutation carriers with lower incidence for carriers of mutations in *MSH6* and *PMS2*. The results for CRC confirmed that colonoscopy fails to prevent a substantial number of CRCs as previously reported.^{3–10} Retrospective studies have provided with different estimates of cancer incidence mostly without colonoscopic surveillance ranging from 22% to 74%. Among the few previous reports from prospective studies,^{3–10} none used methods adjusting for age and many did not discriminate between the patients carrying mutations in the different MMR genes. It is commonly agreed that CRCs may be prevented by colonoscopy, but lacking a control group we could not calculate what proportion this might have been. Also, the CIs of penetrance estimates for the mutated genes both in our and previous studies were too wide to consider a later onset of CRC in our study than in previous reports.

In this first report, we did not include stage at diagnosis of CRC and we could not determine effects of surveillance colonoscopy on the pathological stage at which CRCs were diagnosed, although early diagnosis may be a contributing factor to the excellent long-term survival of CRC that we observed in LS patients. When carrying out the study, we considered <2.5 years and <3.5 years between colonoscopies as compliant

with a guideline of 2-year and 3-year intervals, respectively. As seen in table 6, non-compliance could not explain the majority of the CRC cases. We would like to have more information before considering time since last colonoscopy in more detail, and the database is currently being expanded to include stage at diagnosis, prognosis, synchronous and para-synchronous adenomas and other parameters as a follow-up study based on the current results. Meanwhile, we advocate continuation of the existing surveillance programmes.

Some CRC in LS may have good prognosis¹³ and without a control group it remains theoretically possible that the CRCs occurring in our cohort would have been cured even without surveillance for asymptomatic disease, but a randomised trial denying LS patients access to colonoscopy to test such an hypothesis is unlikely to be justifiable. On the other hand, the purpose of and evidence base for ever more frequent surveillance needs to be revisited, and we will expand our database to address this issue via further studies.

Does the incidence of CRC in LS patients under surveillance indicate that our current approach has failed or is the good survival evidence of success? For LS patients, it is of course survival and quality of life that are the key concerns. This study shows that the former is being achieved while assessment of the latter will require further studies.

Adenomas in the general population are known to cause CRC, and adenomectomy is documented to prevent CRC.¹⁴ Previous reports suggest that incidence of adenomas in LS and late-onset colon cancer families without MMR mutations are similar⁷ while the carcinogenic process from adenoma to carcinoma is accelerated in LS patients.^{7 15} Lack of functioning MMR genes cause microsatellite instability (MSI) and invasive cancers in LS show MSI.¹⁶ Hyperplastic polyps in the colon of LS patients reportedly do not show MSI,¹⁷ while adenomas show increasing loss of MMR gene product and MSI with increasing dysplasia.¹⁶ LS patients may also present MSI in the crypts of a macroscopically normal gut surface.¹⁸ Thus, one may speculate that MMR mutation carriers are capable of producing CRC not only inside an adenoma but also independently of a macroscopically visible adenoma, which in turn may rise several questions: how small the invasive early cancers may be in LS? Which is the sensitivity of colonoscopy to identify such lesions?¹⁹ How rapidly a small preinvasive lesion may progress to invasive cancer? Which is the time window, if any, in a preinvasive macroscopic detectable stage? We are currently expanding the database to address these questions.

Our prospective results do not support major differences in CRC incidence according to gender. Based on assumed carrier status in former generations, differences in CRC incidence by gender have been reported for *MLH1* and *MSH2*,²⁰ but these differences were less notable in a later retrospective study including proven carriers only.²¹




Figure 1 Calculated cumulative incidences by age and mutated gene for any cancer.

Table 5 Calculated cumulative cancer incidences from 25 to 40, 50, 60 or 70 years of age for any cancer and for selected groups of cancers occurring as first cancer, by gender and by mutated gene

Selected group	Age (years)	Calculated cumulative cancer incidence to given age (95% CI) by group and mutated gene			
		<i>MLH1</i>	<i>MSH2</i>	<i>MSH6</i>	<i>PMS2</i>
Any cancer, males and females	40	17% (12.2 to 21.3)	14% (8.3 to 20.3)	0% (–)	0% (–)
	50	40% (34.7 to 45.7)	37% (29.4 to 45.1)	18% (8.0 to 28.3)	0% (–)
	60	59% (52.8 to 64.6)	58% (49.3 to 65.9)	39% (25.8 to 52.2)	18% (0.0 to 41.0)
	70	72% (64.7 to 78.7)	72% (61.9 to 81.2)	54% (38.6 to 68.6)	18% (0.0 to 41.0)
Any cancer, males	40	19% (12.1 to 25.8)	8% (1.2 to 14.3)	0% (–)	0% (–)
	50	40% (31.7 to 47.7)	25% (14.3 to 35.5)	15% (0.0 to 31.3)	0% (–)
	60	55% (46.7 to 64.4)	47% (33.3 to 60.8)	25% (6.0 to 44.5)	0% (–)
	70	59% (49.7 to 68.6)	71% (52.7 to 89.8)	31% (10.3 to 52.3)	0% (to)
Any cancer, females	40	14% (8.4 to 20.5)	20% (10.6 to 29.7)	0% (–)	0% (–)
	50	41% (32.9 to 48.0)	47% (36.2 to 57.8)	20% (6.9 to 33.6)	0% (–)
	60	61% (53.2 to 68.8)	67% (56.6 to 77.0)	48% (30.5 to 65.6)	24% (0.0 to 53.2)
	70	80% (71.2 to 88.8)	75% (64.5 to 85.6)	71% (51.8 to 90.5)	24% (0.0 to 53.2)
CRC, males and females	40	14% (10.0 to 18.7)	9% (4.2 to 14.1)	0% (–)	0% (–)
	50	27% (22.2 to 32.7)	18% (11.4 to 24.4)	2% (0.0 to 5.6)	0% (–)
	60	37% (31.0 to 43.4)	24% (16.1 to 32.0)	10% (0.5 to 19.6)	0% (–)
	70	46% (37.1 to 54.1)	35% (22.4 to 47.1)	20% (4.4 to 35.4)	0% (–)
CRC, males	40	17% (10.3 to 23.5)	8% (1.2 to 14.3)	0% (–)	0% (–)
	50	33% (25.5 to 41.4)	16% (6.7 to 24.5)	0% (–)	0% (–)
	60	44% (35.3 to 53.1)	26% (18.7 to 44.2)	6% (0.0 to 18.8)	0% (–)
	70	47% (36.9 to 56.1)	37% (19.5 to 53.6)	14% (0.0 to 32.2)	0% (–)
CRC, females	40	11% (6.2 to 17.5)	11% (3.1 to 18.3)	0% (–)	0% (–)
	50	21% (14.6 to 28.3)	20% (10.6 to 29.6)	3% (0.0 to 9.8)	0% (–)
	60	30% (21.9 to 38.9)	22% (12.2 to 32.5)	12% (0.0 to 25.9)	0% (–)
	70	45% (31.1 to 59.3)	33% (16.3 to 48.9)	26% (0.0 to 54.2)	0% (–)
Endometrial cancer, females	40	3% (0.1 to 5.9)	2% (0.0 to 4.7)	0% (–)	0% (–)
	50	18% (11.3 to 24.7)	15% (6.0 to 24.6)	16% (3.1 to 28.6)	0% (–)
	60	34% (24.2 to 44.3)	44% (29.3 to 58.2)	40% (19.5 to 61.4)	24% (0.0 to 52.8)
	70	34% (24.2 to 44.3)	51% (32.7 to 69.2)	49% (25.3 to 73.5)	24% (0.0 to 52.8)
Ovarian cancer, females	40	1% (0.0 to 3.6)	4% (0.0 to 8.9)	0% (–)	0% (–)
	50	7% (2.2 to 11.2)	12% (4.2 to 20.2)	0% (–)	0% (–)
	60	9% (2.9 to 13.2)	15% (5.5 to 24.4)	0% (–)	0% (–)
	70	11% (3.2 to 19.8)	15% (5.5 to 24.4)	0% (–)	0% (–)
Upper GI cancer; males and females	40	0.4% (0.0 to 1.1)	0% (–)	0% (–)	0% (–)
	50	2% (0.5 to 4.1)	3% (0.0 to 5.7)	0% (–)	0% (–)
	60	7% (2.4 to 10.4)	5% (0.6 to 10.5)	2% (0.0 to 6.3)	0% (–)
	70	18% (7.2 to 27.6)	5% (0.6 to 10.5)	2% (0.0 to 6.3)	0% (–)
Urinary tract cancer; males and females	40	0% (–)	0% (–)	0% (–)	0% (–)
	50	1% (0.0 to 2.2)	1% (0.0 to 2.3)	4% (0.0 to 9.4)	0% (–)
	60	2% (0.0 to 3.3)	7% (1.8 to 15.1)	4% (0.0 to 9.4)	0% (–)
	70	2% (0.0 to 3.3)	20% (4.1 to 33.9)	9% (0.0 to 19.3)	0% (–)

Cancers included were colorectal (CRC), endometrial, ovarian, upper GI (including gastric, pancreatic, biliary tract and duodenal cancers) and urinary tract cancers (including kidney, calyx, ureter and urinary bladder) in LS patients without prior or prevalent cancer at first colonoscopy.

Regarding specific genes, *MSH6* carriers had later onset of any cancer and of CRC than *MLH1* and *MSH2* carriers, in line with previous reports. The low number of *MSH6* and *PMS2* observation years most probably represents an ascertainment error linked to their lower penetrance²² and to the less widespread availability of diagnostic testing for these genes. Also, the age distributions may have been influenced by *MSH6* mutation carriers presenting to genetic clinics at older ages after their relatives had already developed cancers. In spite of these uncertainties, our results question current guidance that advises that *MSH6* carriers should commence colorectal surveillance at young ages.^{1 2} A study of a larger cohort of young mutation carriers is needed to draw firm conclusions.

The higher cumulative incidence of any cancer at age 70 years in females (75%) versus males (58%) may be a consequence of the incidences of endometrial and ovarian cancers in females. Endometrial cancer cumulative incidence at 70 years was consistently high for *MLH1* (34%), *MSH2* (51%) and *MSH6* (49%) and notable in *PMS2* carriers (24%). Ovarian cancer cumulative

incidence at 70 years was lower and restricted to *MLH1* (11%) and *MSH2* (15%) carriers. In our series, 21/314 (7%) of the cases identified with first cancers had two synchronous cancers in different organs, suggesting that the risk of getting a new primary cancer may be increased in those having already had one or more cancers or precursor lesions.^{1 2} There is limited prospectively observed evidence, however, on the magnitude of such risks. The methods used in this study are not suitable for calculation of these risks. Neither does our study provide information on cancer risks in LS patients under 25 years of age. As the clinical guidelines used in our collaborating centres suggest starting surveillance at this age, we could not consider AIR for younger patients. Because colonoscopic surveillance did not prevent all CRC in *MLH1* and *MSH2* carriers, it is unlikely that it did so in *MSH6* and *PMS2* carriers. Our findings make it very unlikely that *MSH6* or *PMS2* mutation carriers develop a significant number of LS-associated cancers before 25 years, but a small proportion of *MLH1* and *MHS2* mutation carriers may do so. Our results have no bearing on the current guidelines that




Figure 2 Calculated cumulative incidences by age and mutated gene for colorectal cancer (CRC) as the first cancer.

suggest surveillance only after age 25 years for *MLH1* and *MSH2* mutation carriers.

The three major LS-associated cancer types, CRC, endometrial and ovarian, all had excellent observed survival, which is very encouraging for carriers of MMR gene mutations. Further investigation will be needed to determine the degree to which this good prognosis is the result of early detection due to surveillance, improved prognosis due to detection at early stages, lead time bias due to early detection and/or represents a better prognosis for cancers in LS patients than for cancers arising in the general population. Relevant factors might include the high degree of immunogenicity and paucity of progressive metastatic disease in LS CRCs^{13 23} and the efficacy of current treatments in the patient group.

Most ovarian cancers in LS were cured, consistent with our previous study,²² and the same was true for endometrial cancers. Also, our findings support the notion that LS ovarian cancers have a good prognosis when given current




Figure 3 Calculated cumulative incidences by age and mutated gene for endometrial cancer as the first cancer by gene.

Table 6 Time since last colonoscopy in months; and number, cumulative number and cumulative % of colorectal cancer (CRC) cases diagnosed in each time interval

Months since last colonoscopy	Number of cases	Cumulative number of cases	Cumulative %
0–5	0	0	0
6–11	9	9	6
12–17	23	32	22
18–23	13	45	31
24–29	39	84	58
30–35	10	94	65
36–41	21	115	79
42–59	18	133	92
60–125	12	145	100

Six cases counted once here had two synchronous CRCs, cf table 2 showing 151 CRC diagnoses.

treatment.^{24 25} This good prognosis may be partly the result of early detection due to surveillance, but pathological and molecular genetic analysis have also indicated more favourable tumour characteristics in LS-associated ovarian cancers compared with sporadic disease.^{26 27} This is in sharp contrast to *BRCA1/2* ovarian cancer cases that have a poor prognosis despite early detection and treatment.²⁸ The cumulative incidence for ovarian cancer in *MLH1* and *MSH2* carriers up to 50 years of age was similar to reported cumulative incidence in *BRCA1* carriers²⁸ but with lower incidence later in life. The finding that ovarian cancer was restricted to *MLH1* and *MSH2* mutation carriers was unexpected and needs validation.

Certain characteristics of the methods we used need to be highlighted. The calculation of cumulative incidence by age is based upon the observed point estimates for annual incidence for each age group. The method adjusts for uneven distribution of numbers in the different age groups, and for the different distributions of ages of patients by mutated gene. If we had estimated penetrance by gene from inclusion to last observation using the Kaplan–Meier algorithm, equal AIR in all age groups had to be assumed for each gene. If doing so, we would have compared younger *MLH1/MSH2* carriers to older *MSH6/PMS2* carriers. Assimilating our data into one larger database was mandatory to arrive at sufficient numbers to use our method to calculate AIR by age and thereby estimate cumulative incidences by age, mutated gene and gender. If doing so, we avoided many ascertainment and time-trend biases present in retrospective family studies that were previously used to determine

Table 7 5-year and 10-year crude survival after first cancer diagnosed by cancer type in Lynch syndrome (LS) patients without prior or prevalent cancer at first colonoscopy

Group	Number cases	5-year survival (95% CI)	10-year survival (95% CI)
Any cancer	301	90% (86 to 93)	87% (83 to 91)
Colorectal cancer	140	94% (90 to 98)	91% (84 to 95)
Endometrial cancer	71	98% (88 to 99.8)	98% (88 to 99.8)
Ovarian cancer	19	88% (60 to 97)	89% (60 to 97)
Upper GI cancer	24	58% (36 to 75)	53% (31 to 71)
Urinary tract cancer	17	82% (51 to 93)	73% (42 to 89)

penetrance, and patient numbers were sufficient to adjust for skewed distributions by age and mutated gene.

In spite of the strengths, this study has some limitations. The cumulative incidences presented are not cumulative incidences for organ-specific cancers, but for any first cancers and for the organ in which the first cancers occurred. Calculation of cumulative incidence by age for specific cancers irrespective of the occurrence of other cancers will need a different data set and specific methods, and the database is currently being expanded to do so. The long period (>20 years) of observation is likely to span improvements in techniques for early diagnosis of cancer, as well as treatment, both of which may improve survival. Assuming that shorter time between colonoscopies and/or that recent treatment is possibly better than the average during the period reported, our results may be considered worst-case estimates.

The information provided here should help in the genetic counselling of individual patients. We have made it available via an interactive open access website for personalised healthcare at <http://www.LScarisk.org>. Based on the algorithm given above and the information given in online supplementary table S1, the website calculates the cumulative risk of developing cancer from any age selected by the user to any age up to 70 years for any currently unaffected patient with LS by entering age, gender and mutated gene. The website may be used for any single patient to provide personalised risk estimates for all groups of cancers detailed in [table 5](#).

The findings presented here raise a number of questions that will be addressed by further studies: the effects of colonoscopy intervals on CRC incidence; whether or not CRC in LS may emerge outside a macroscopic visible adenoma, time to subsequent cancer in LS patients surviving their first cancers; the lifetime risk for any specific cancer in those surviving the other cancer types; the disease-specific survival for all distinct cancer types; and investigation of the penetrance and expression of different classes of mutations at each MMR gene locus. We are currently expanding the database to address these key questions. As the numbers of young *MSH6* or *PMS2* mutation carriers we have been able to include have been limited so far, we welcome other parties with such series to join us and contribute to future refinement of incidence rates for *MSH6* and *PMS2* mutation carriers.

For further information on the collaborating activities, please visit <http://insight-group.org/> and <http://mallorca-group.eu/>. To tailor cancer risk prediction according to a given patient's age, gender and mutated gene, visit <http://LsCaRisk.org>.

Author affiliations

¹Research Group Inherited Cancer, Department of Medical Genetics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway

²Department of Surgery, Central Finland Health Care District, Jyväskylä, Finland

³Danish HNPCC Register; Hvidovre University Hospital, Copenhagen, Denmark

⁴Department Surgical Gastroenterology, Aalborg University Hospital, Aalborg, Denmark

⁵Medizinische Klinik und Poliklinik IV, Campus Innenstadt, Klinikum der Universität München, Ziemssenstr. 1, Munich, Germany

⁶MGZ—Medizinisch Genetisches Zentrum, Munich, Germany

⁷Unit of Hereditary Digestive Tract Tumors IRCCS Istituto Nazionale Tumori, Milan, Italy

⁸Manchester Centre for Genomic Medicine, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK

⁹Manchester Centre for Genomic Medicine, University of Manchester, Manchester, UK

¹⁰Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden

¹¹Colorectal Medicine and Genetics, The Royal Melbourne Hospital, Melbourne, Australia

¹²Department of Medicine, Melbourne University, Melbourne, Australia

¹³Hereditary Cancer Program, Institut Català d'Oncologia-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain

¹⁴Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

¹⁵Institute of Medical Genetics, Cardiff University School of Medicine, Heath Park, Cardiff, UK

¹⁶Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Leiden, The Netherlands

¹⁷Institute of Genetic Medicine Newcastle University, Newcastle upon Tyne, UK

¹⁸Department of Tumor Biology, Institute of Cancer Research, The Norwegian Radium Hospital, part of Oslo University Hospital, Oslo, Norway

¹⁹Institute of Cancer Genetics and Informatics, The Norwegian Radium Hospital, part of Oslo University Hospital, Oslo, Norway

²⁰Department of Informatics, University of Oslo, Oslo, Norway

²¹Department of Mathematics, University of Oslo, Oslo, Norway.

²²Department of Gastroenterology and Hepatology, Isala Clinics, Zwolle, The Netherlands

²³Department of Surgery, Central Manchester University Hospitals NHS Foundation Trust and University of Manchester, Manchester, UK

²⁴Department of Clinical Genetics and Department of Human Genetics Leiden University Medical Centre, Leiden, The Netherlands

²⁵Department of Clinical Genetics, Aarhus University Hospital, Aarhus, Denmark

²⁶Department of Biomedicine, Aarhus University, Aarhus, Denmark

²⁷Division of Obstetrics and Gynecology, Department of Women's and Children's health, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden

²⁸Department of Surgery, Helsinki University Hospital, Helsinki, Finland

²⁹Genome-Scale Biology Research Program, University of Helsinki, Helsinki, Finland

³⁰Department of Education and Science, Central Finland Health Care District, Jyväskylä, Finland

³¹University of Eastern Finland, Jyväskylä, Finland

³²Department of Surgery, HELIOS St Josefs Hospital Bochum-Linden (Helios), Bochum, Germany

Twitter Follow Toni Seppälä at @Adductor and Ignacio Blanco at @consejogenetico

Contributors PM: managed database and calculated results. PM, JB, GC, IMF, FM and JS drafted the manuscript. EAR, KT, SN and EH calculated the CIs. SN and EH established the website. All participated in study design, interpretation of results, writing of manuscript and approved final manuscript.

Funding The Finnish contribution was supported by The Finnish Cancer Foundation, The Sigrid Juselius Foundation, Mary and Georg Ehrnrooth foundation and State Research Funding. The Spanish contribution has been funded by the Spanish Ministry of Economy and Competitiveness SAF2012-33636 (GC); the Carlos III Health Institute; RTICC (RD12/0036/0008); the Scientific Foundation Asociación Española Contra el Cáncer; and the Government of Catalonia (2014 SGR 338) and the Welsh Contribution by the Wales Gene Park.

Competing interests JB has a patent for high-speed low-cost tumour profiling pending to JB and QuantuMDx. DGE is a NIHR senior investigator.

Patient consent Obtained.

Ethics approval Ethical approval for health service and/or health service as research project as described.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement There are no unpublished data to the current ends. Additional results will be published from additional data. Each contributor has the authority to distribute own data to anyone without permission from the group. No patient identifiable data were exported from any participating centre.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

REFERENCES

- Vasen HF, Blanco I, Aktan-Collan K, *et al*. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. *Gut* 2013;62:812–23.
- Giardiello FM, Allen JJ, Axilbund JE, *et al*. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-society Task Force on colorectal cancer. *Am J Gastroenterol* 2014;109:1159–79.
- Stormorken AT, Clark N, Grindedal E, *et al*. Prevention of colorectal cancer by colonoscopic surveillance in families with hereditary colorectal cancer. *Scand J Gastroenterol* 2007;42:611–17.

- 4 Järvinen HJ, Renkonen-Sinisalo L, Aktán-Collán K, *et al.* Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. *J Clin Oncol* 2009;27:4793–7.
- 5 Engel C, Rahner N, Schulmann K, *et al.* Efficacy of annual colonoscopic surveillance in individuals with hereditary nonpolyposis colorectal cancer. *Clin Gastroenterol Hepatol* 2010;8:174–82.
- 6 Vasen HF, Abdirahman M, Brohet R, *et al.* One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome. *Gastroenterology* 2010;138:2300–6.
- 7 Burn J, Gerdes AM, Macrae F, *et al.* Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. *Lancet* 2011;378:2081–7.
- 8 Stuckless S, Green JS, Morgenstern M, *et al.* Impact of colonoscopic screening in male and female Lynch syndrome carriers with an MSH2 mutation. *Clin Genet* 2012;82:439–45.
- 9 Snowsill T, Huxley N, Hoyle M, *et al.* A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome. *Health Technol Assess* 2014;58:1–406.
- 10 Newton K, Green K, Lalloo F, *et al.* Colonoscopy screening compliance and outcomes in patients with Lynch syndrome. *Colorectal Dis* 2015;17:38–46.
- 11 Jenkins MA, Dowty JG, Ait Ouakrim D, *et al.* Short-term risk of colorectal cancer in individuals with lynch syndrome: a meta-analysis. *J Clin Oncol* 2015;33:326–31.
- 12 Møller P, Clark N. CGEN—a Clinical GENetics software application. *Hum Mutat* 2011;32:537–42.
- 13 Tikidzhieva A, Benner A, Michel S, *et al.* Microsatellite instability and Beta2-Microglobulin mutations as prognostic markers in colon cancer: results of the FOGT-4 trial. *Br J Cancer* 2012;106:1239–45.
- 14 Samadder NJ, Curtin K, Pappas L, *et al.* Risk of incident colorectal cancer and death after colonoscopy: a population-based Study in Utah. *Clin Gastroenterol Hepatol* 2015. Published Online First.
- 15 De Jong AE, Morreau H, Van Puijenbroek M, *et al.* The role of mismatch repair gene defects in the development of adenomas in patients with HNPCC. *Gastroenterology* 2004;126:42–8.
- 16 Pino MS, Mino-Kenudson M, Wildemore BM, *et al.* Deficient DNA mismatch repair is common in Lynch syndrome-associated colorectal adenomas. *J Mol Diagn* 2009;11:238–47.
- 17 Speake D, O’Sullivan J, Evans DG, *et al.* Hyperplastic polyps are innocuous lesions in hereditary nonpolyposis colorectal cancers. *Int J Surg Oncol* 2011;2011:653163.
- 18 Staffa L, Echterdiek F, Nelius N, *et al.* Mismatch repair-deficient crypt foci in Lynch syndrome—molecular alterations and association with clinical parameters. *PLoS ONE* 2015;10:e0121980.
- 19 Dik VK, Gralnek IM, Segol O, *et al.* Multicenter, randomized, tandem evaluation of EndoRings colonoscopy—results of the CLEVER study. *Endoscopy* 2015. Published Online First.
- 20 Vasen HF, Stormorken A, Menko FH, *et al.* MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. *J Clin Oncol* 2001;19:4074–80.
- 21 Hendriks YM, Wagner A, Morreau H, *et al.* Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. *Gastroenterology* 2004;127:17–25.
- 22 Sjursen W, Haukanes BI, Grindedal EM, *et al.* Current clinical criteria for Lynch syndrome are not sensitive enough to identify MSH6 mutation carriers. *J Med Genet* 2010;47:579–85.
- 23 Reuschenbach M, Kloor M, Morak M, *et al.* Serum antibodies against frameshift peptides in microsatellite unstable colorectal cancer patients with Lynch syndrome. *Fam Cancer* 2010;9:173–9.
- 24 Grindedal EM, Renkonen-Sinisalo L, Vasen H, *et al.* Survival in women with MMR mutations and ovarian cancer: a multicentre study in Lynch syndrome kindreds. *J Med Genet* 2010;47:99–102.
- 25 Lynch HT, Casey MJ, Snyder CL, *et al.* Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. *Mol Oncol* 2009;3:97–137.
- 26 Niskakoski A, Kaur S, Renkonen-Sinisalo L, *et al.* Distinct molecular profiles in Lynch syndrome-associated and sporadic ovarian carcinomas. *Int J Cancer* 2013;133:2596–608.
- 27 Niskakoski A, Kaur S, Staff S, *et al.* Epigenetic analysis of sporadic and Lynch-associated ovarian cancers reveals histology-specific patterns of DNA methylation. *Epigenetics* 2014;9:1577–87.
- 28 Finch AP, Lubinski J, Møller P, *et al.* Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. *J Clin Oncol* 2014;32:1547–53.